Location
Suwanee, GA
Start Date
17-4-2026 12:00 PM
End Date
17-4-2026 1:00 PM
Description
The rise of multi drug resistant Acinetobacter baumannii, a pathogen classified by the WHO as a critical priority organism has created an urgent need for innovative antimicrobial therapies. Abaucin is a novel small molecule antibiotic identified through an artificial intelligence driven drug discovery platform. The machine learning platform was used to create a predictive algorithm on 7500 known compounds against A. baumannii to identify structural features associated with bacterial growth inhibition. This algorithm analyzed 6,680 additional compounds from a drug repurposing hub, rapidly identifying several candidates for experimental validation. Anti-bacterial activity screening of 240 selected compounds yielded nine active antibiotics, including abaucin, a molecule originally investigated for diabetes therapy. Abaucin demonstrated potent in vitro anti-bacterial activity against multiple drug resistant A. baumanni strains while exhibiting no activity against other major pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus, highlighting its narrow spectrum specificity. Further study on abaucin’s mechanism of action revealed that abaucin disrupts lipoprotein trafficking by inhibiting the transmembrane protein LoIE, leading to impaired outer membrane maintenance and bacterial cell death. In the pre-clinical trial using mice, the effectiveness of abaucin for wound infection caused by A. baumannii, showed significant reduction in bacterial burden and tissue inflammation, representing the first in vivo validation of an AI discovered antibiotic targeting A. baumannii. Although abaucin remains in the preclinical stage and has not received FDA approval, its pathogen specific activity, novel mechanism of action and AI-guided discovery distinguish it from traditional broad-spectrum agents. Abaucin represents a promising investigational therapy and underscores the potential of AI-driven approaches in accelerating anti-microbial drug discovery against multidrug resistant pathogens.
Embargo Period
6-1-2026
Included in
AI driven discovery of Abaucin: A Novel Narrow-spectrum Antibiotic Targeting Multidrug Resistant Acinetobacter baumannii
Suwanee, GA
The rise of multi drug resistant Acinetobacter baumannii, a pathogen classified by the WHO as a critical priority organism has created an urgent need for innovative antimicrobial therapies. Abaucin is a novel small molecule antibiotic identified through an artificial intelligence driven drug discovery platform. The machine learning platform was used to create a predictive algorithm on 7500 known compounds against A. baumannii to identify structural features associated with bacterial growth inhibition. This algorithm analyzed 6,680 additional compounds from a drug repurposing hub, rapidly identifying several candidates for experimental validation. Anti-bacterial activity screening of 240 selected compounds yielded nine active antibiotics, including abaucin, a molecule originally investigated for diabetes therapy. Abaucin demonstrated potent in vitro anti-bacterial activity against multiple drug resistant A. baumanni strains while exhibiting no activity against other major pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus, highlighting its narrow spectrum specificity. Further study on abaucin’s mechanism of action revealed that abaucin disrupts lipoprotein trafficking by inhibiting the transmembrane protein LoIE, leading to impaired outer membrane maintenance and bacterial cell death. In the pre-clinical trial using mice, the effectiveness of abaucin for wound infection caused by A. baumannii, showed significant reduction in bacterial burden and tissue inflammation, representing the first in vivo validation of an AI discovered antibiotic targeting A. baumannii. Although abaucin remains in the preclinical stage and has not received FDA approval, its pathogen specific activity, novel mechanism of action and AI-guided discovery distinguish it from traditional broad-spectrum agents. Abaucin represents a promising investigational therapy and underscores the potential of AI-driven approaches in accelerating anti-microbial drug discovery against multidrug resistant pathogens.